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Recent advances in fluorescent ligand technology have enabled the study of G
protein-coupled receptors in their native environment without the need for genetic
modification such as addition of N-terminal fluorescent or bioluminescent tags. Here,
we have used a non-imaging plate reader (PHERAstar FS) to monitor the binding
of fluorescent ligands to the human adenosine-A3 receptor (A3AR; CA200645 and
AV039), stably expressed in CHO-K1 cells. To verify that this method was suitable
for the study of other GPCRs, assays at the human adenosine-A1 receptor, and β1
and β2 adrenoceptors (β1AR and β2AR; BODIPY-TMR-CGP-12177) were also carried
out. Affinity values determined for the binding of the fluorescent ligands CA200645
and AV039 to A3AR for a range of classical adenosine receptor antagonists were
consistent with A3AR pharmacology and correlated well (R
2 = 0.94) with equivalent
data obtained using a confocal imaging plate reader (ImageXpress Ultra). The binding
of BODIPY-TMR-CGP-12177 to the β1AR was potently inhibited by low concentrations
of the β1-selective antagonist CGP 20712A (pKi 9.68) but not by the β2-selective
antagonist ICI 118551(pKi 7.40). Furthermore, in experiments conducted in CHO K1
cells expressing the β2AR this affinity order was reversed with ICI 118551 showing the
highest affinity (pKi 8.73) and CGP20712A (pKi 5.68) the lowest affinity. To determine
whether the faster data acquisition of the non-imaging plate reader (∼3 min per 96-well
plate) was suitable for high throughput screening (HTS), we screened the LOPAC
library for inhibitors of the binding of CA200645 to the A3AR. From the initial 1,263
compounds evaluated, 67 hits (defined as those that inhibited the total binding of
25 nM CA200645 by ≥40%) were identified. All compounds within the library that had
medium to high affinity for the A3AR (pKi ≥6) were successfully identified. We found
three novel compounds in the library that displayed unexpected sub-micromolar affinity
for the A3AR. These were K114 (pKi 6.43), retinoic acid p-hydroxyanilide (pKi 6.13) and
SU 6556 (pKi 6.17). Molecular docking of these latter three LOPAC library members
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provided a plausible set of binding poses within the vicinity of the established orthosteric
A3AR binding pocket. A plate reader based library screening using an untagged receptor
is therefore possible using fluorescent ligand opening the possibility of its use in
compound screening at natively expressed receptors.
Keywords: adenosine receptors, fluorescent ligands, adenosine A3 receptor, high throughput screening, LOPAC
library
INTRODUCTION
G protein-coupled receptors (GPCRs) represent the largest
family of cell surface receptors and account for approximately 4%
of the entire protein-coding human genome. There are
approximately 700 separate GPCRs of which over 300 are non-
olfactory receptors (Kuder and Kiec´-Kononowicz, 2014). Based
on sequence homology, five distinct families of non-olfactory
receptors have been proposed: Family A/Rhodopsin, Family
B/secretin, Adhesion GPCRs, Family C/Glutamate, and Family
F/frizzled (Guo et al., 2012). Family A contains the largest
number of the non-olfactory GPCRs including many of the
most widely studied receptors, each of which acts to translate
extracellular signals into intracellular effects by activating both
heterotrimeric G protein-dependent and -independent signaling
cascades (Castro et al., 2005; Guo et al., 2012). Importantly, these
family A GPCRs are also currently targeted by a large number
of clinically used drugs and are validated targets for a significant
number of drug discovery programmes.
Adenosine is one biological transmitter which plays a vital
homeostatic role and acts via a family of Class A GPCRs
comprising four distinct subtypes: namely the adenosine-A1
receptor (A1AR), A2AAR, A2BAR, and A3AR (Fredholm et al.,
2011). Both the A1AR and A3ARs inhibit intracellular cAMP
formation by activating inhibitory Gi proteins, whilst the A2AAR
and A2BARs generally stimulate cAMP formation via stimulatory
Gs proteins. Adenosine-mediated signaling has been implicated
in a number of pathological states. For instance, the signaling
pathways regulated by these receptors can promote angiogenesis
(Headrick et al., 2013) and reduce inflammation (Antonioli et al.,
2014). Within this family, the A3AR is a promising molecular
target for the control of a range of pathological conditions
including cancer (Montinaro et al., 2013; Nakamura et al., 2015;
Cao et al., 2017; Joshaghani et al., 2017), inflammation (Cohen
et al., 2014; Yoshida et al., 2017), autoimmune diseases (Ravani
et al., 2017), ischaemia (Mulloy et al., 2013; González-Fernández
et al., 2014; Hussain et al., 2014; Ohana et al., 2016) and chronic
neuropathic pain (Little et al., 2015; Tosh et al., 2015), making it
an important target for drug development (Borea et al., 2015). As
a consequence, identifying new screening methods for discovery
of novel chemical scaffolds which bind to the A3AR would be
beneficial.
With this in mind, it is of note that recent advances in
fluorescent ligand technology have enabled unlabeled GPCRs to
be studied in their native environment without any need for
genetic modification through the addition of a bioluminescent
or fluorescent tag. For instance fluorescent ligands have been
used to study various aspects of GPCR pharmacology including
ligand binding, receptor-ligand kinetics, receptor localization
and trafficking (Stoddart et al., 2015b). Of particular relevance
to purinergic drug discovery, Stoddart et al. (2012) developed a
competitive binding assay for the human A3AR and A1AR in
live cells, using a high content screening (HCS) platform that
allowed the screening of small fragment libraries. This assay
system was also used to validate the pharmacology of A3AR
selective compounds that were identified from virtual screening
of homology models (Ranganathan et al., 2015). However, a
disadvantage of this technique is that it involves the acquisition
and analysis of a large number of images which can impose severe
time, data handling and storage limitations at the early stages
of drug discovery, particularly in hit discovery, when very large
libraries (>100,000 compounds) are used in initial screening
campaigns (Tomasch et al., 2012). In this work, we show that
such a competitive fluorescent based binding screen is possible
on a higher throughput, non-imaging-based platform using two
structurally unrelated fluorescent antagonists. The suitability of
this assay for higher throughput screens has been demonstrated
by screening a library of pharmacological active compounds
(LOPAC) against the native human A3AR in living cells, with a
view to identifying potential novel scaffolds for A3AR ligands.
RESULTS
Comparison of High Content (HCS) and
High Throughput (HTS) Screening
Platforms for Measuring Competition
Binding to the A3AR
As previously described, competition binding assays have been
performed on cells expressing the wild type human A3AR
using the fluorescent adenosine receptor antagonist CA200645
by automated image acquisition using an ImageXpress (IX)
Ultra confocal imaging plate reader (Stoddart et al., 2012).
In order to see if this method could be translated into a
faster non-imaging format, we directly compared HCS and
plate reader based CA200645 binding by sequentially reading
the same samples on the PHERAstar FS (BMG technologies)
then the IX Ultra. As shown in the IX Ultra plate image in
Figure 1A, binding of 25 nM CA200645 was clearly detected,
and was subsequently displaced by increasing concentrations
of competing (unlabeled) antagonists. The same 96-well plate
was also measured on a standard non-imaging fluorescence
plate reader (PHERAstar FS), with 81 separate repeat reads
per well to take into account variation in cell density, and
a similar pattern of fluorescence was observed (Figure 1B).
The montage images from both instruments show that the
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FIGURE 1 | Competition binding at the A3AR using fluorescent ligands. CHO cells expressing the A3AR were incubated with 25 nM CA200645 and increasing
concentrations of MRS1220, XAC, or AV019. (A) Four images per well were obtained on the IX Ultra confocal plate reader and resulting images shown as a montage.
(B) Montage fluorescence intensity measurement of the same plate obtained using the FS PHERAstar where blue, green, yellow and red pixels represents increasing
intensity of fluorescence. (C) Competition curves at the A3AR generated from the total fluorescence intensity measured on the PHERAstar FS microplate reader for
five adenosine receptor antagonists. (D) CHO A3AR cells were incubated with increasing concentrations of antagonist and 5 nM AV039 for 1 h, 37
◦C, washed and
fluorescence intensity assessed using the PHERAstar FS. (E) Correlation between pKi values obtained using the IX Ultra (high content screening; HCS) and the
PHERAstar FS (high throughput screening; HTS) for the data obtained using CA200645 as fluorescent ligand. Data were normalized to the maximal intensity observed
per experiment and each data point represents the mean ± SEM from n number of experiments (See Table 1) performed in triplicate.
high affinity A3AR antagonist MRS1220, AV019 (compound
1 in Vernall et al., 2012) and the non-selective adenosine
receptor antagonist xanthine amine congener (XAC) caused a
concentration-dependent reduction in the fluorescence intensity
observed with 25 nM CA200645 alone. Competition binding
curves were generated from the quantified data (Figure 1C), and
pKi values for the five adenosine receptor antagonists obtained,
which were comparable to values reported in the literature
(Table 1). Comparison of the affinity values from the HTS
platform (PHERAstar) to those from theHCS platform (IXUltra)
showed a high degree of correlation (R2 = 0.94) (Figure 1E) and
we have previously shown that affinity values obtained from the
HCS platform correlated well with values obtained in a functional
assay (Stoddart et al., 2012). In addition to the XAC based
fluorescent ligand CA200645, a structurally distinct and highly
selective fluorescent A3AR antagonist was also used (AV039;
compound 19 in Vernall et al., 2012). As with CA200645, using
5 nMAV039 as label, competition binding experiments measured
on the PHERAstar FS produced the expected rank order of
antagonist affinity for the A3AR (Figure 1D, Table 1).
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TABLE 1 | Affinity of compounds measured at the A1AR and A3AR: Affinity values from the PHERAstar HTS assay for unlabeled ligands measured on CHO cells
expressing the A3AR or the A1AR using 25 nM CA200645 or 5 nM AV039.
A3AR Literature values A1AR Literature values
CA200645 AV039 CA200645
pKi n pKi n pKi n
MRS1220 9.30 ± 0.32 5 9.21 ± 0.12 6 9.02 7.35 ± 0.19 5 7.14
AV019 8.82 ± 0.28 4 ND – 8.51 ND – 5.93
XAC 8.06 ± 0.16 5 8.04 ± 0.22 4 7.85 7.70 ± 0.08 4 7.54
CGS15943 7.91 ± 0.20 3 7.91 ± 0.01 3 8.18 8.35 ± 0.16 3 8.95
ZM241385 6.63 ± 0.20 3 6.32 ± 0.28 3 6.74 6.54 ± 0.04 3 6.68
Values represent mean ± SEM from n number of experiments performed in triplicate. ND, Not determined. Literature values for both A3AR and A1AR taken from Stoddart et al. (2012).
Application to A1AR and β-Adrenoceptors
To verify that the experimental approach used for the A3AR was
suitable for the study of other GPCRs, we conducted the same
experimental design with CA200645 on CHO cells expressing
the human A1AR, since this fluorescent ligand also binds with
high affinity to this receptor (Stoddart et al., 2012). This is
important, since being able to screen for compound selectivity
is an important aspect of developing a screening methodology.
As with the A3AR, a clear concentration-dependent decrease
in fluorescence intensity was detected on the HTS plate reader
in the presence of four different adenosine receptor antagonists
(Figure 2A). The affinity values from these data were consistent
with A1AR pharmacology with CGS 15943 showing the highest
affinity and MRS1220 exhibiting a lower affinity than at the
A3AR. In addition, ZM241385, an A2AAR selective antagonist
showed the expected low affinity at the A1AR (Table 1).
The confocal based fluorescent ligand binding assay has also
been recently applied to study the pharmacology of the β1AR
using BODIPY-TMR labeled CGP 12177 (BODIPY-TMR-CGP;
Gherbi et al., 2014) and we therefore also tested whether ligand
binding to the β1AR and β2AR could also be monitored using
the HTS platform in order to develop a counter screen for the
A3AR. As shown in Figure 2B, in CHO cells expressing either the
β1AR or β2AR, binding of BODIPY-TMR-CGP could be clearly
detected, and clear competition binding was observed with all
three βAR ligands at both receptors. Importantly, the β1AR
selective antagonist CGP 20712A displayed the highest affinity
at the β1AR and the β2AR selective antagonist ICI 118551 the
lowest (Table 2), whilst this rank order was reversed at the β2AR,
with ICI 118551 showing the highest affinity and CGP20712A the
lowest affinity (Figure 2C, Table 2).
Screening of a Focused Library of
Pharmacologically Active Ligands at the
A3AR
To determine whether the HTS version of the competitive
fluorescent binding assay was suitable for the screening of
large compound libraries, we chose to screen the Library of
Pharmacologically Active Compounds (LOPAC) against the
A3AR. The LOPAC library is considered to be a recognized
standard for assay validation as it is based on an extensive
number of bioactive compounds. Many of these are known
to affect targets involved in adenosine receptor signaling
(Iturrioz et al., 2010). CHO cells expressing the A3AR were
grown to confluency in 96-well plates and incubated with a
single concentration (10µM) of the known A3AR antagonist
MRS1220 as a positive control or one of the 1,263 compounds
(10µM) from the LOPAC library and CA200645 (25 nM)
and the fluorescence intensity of each well determined on
the PHERAstar FS plate reader as described in Experimental
Procedures. Hits were defined as those compounds which
inhibited the binding of CA200645 by >40%, and of the initial
1263 compounds evaluated, 67 hits were identified (Supporting
Information Table 1, Figure 3, Table 3). Inhibition data for
all the compounds tested in the initial screen can be found
in Supporting Information Table 1. Among the hits, all the
compounds within the library with medium to high affinity for
the A3AR (pKi ≥6; Figure 3, Table 3) were identified along with
four low affinity adenosine-related molecules (1,3-dipropyl-8-
p-sulfophenylxanthine, DMPX, etazolate hydrochloride and 2-
phenylaminoadenosine; Table 3). This confirmed the utility of
this approach to identify compounds with known A3AR binding
affinity. Importantly, the assay Z’ factor was 0.47± 0.03 (mean±
SEM, n = 97), demonstrating its suitability for screening larger
libraries in living cells.
Ten hits from the initial screen which demonstrated the
biggest inhibition of CA200645 binding to the A3AR were
investigated further and full inhibition curves for each compound
were generated. We were unable to further test reactive blue
2 (position 4 in the full screen) as it is currently not available
commercially. As shown in Figure 4, Table 4, four of the
top ten compounds showed low- to sub-micromolar affinity
for the A3AR. As expected the adenosine receptor antagonist
CGS15943 displaced the binding of CA200645 at both the
A3AR and A1AR in a concentration-dependent manner with
the expected affinity (Figure 4, Table 1). As CGS15943 was
one of the top ten hits from the initial screen it was also
tested in cells expressing the β2AR and had no effect on
the binding of BODIPY-TMR-CGP (Figure 4). Three further
compounds, retinoic acid p-hydroxyanilide (fenretinide), K114
and SU 6656, were found to inhibit the binding of CA20065
to the A3AR in a concentration-dependent manner with
affinity values in the sub-micromolar range, roughly 10-fold
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FIGURE 2 | Competition binding assays at the adenosine A1 and
β1/β2-adrenoceptors. CHO cell lines stably expressing A1AR (A), β1AR (B) or
the β2AR (C) were incubated with 25 nM CA200645 (A1AR) or 10 nM
BODIPY-TMR-CGP (β1AR and β2AR), in the absence or the presence of
increasing concentrations of antagonists. Fluorescence intensity in each well
was monitored using the PHERAstar FS. Values are mean ± SEM from 3–6
independent experiments performed in triplicate.
TABLE 2 | Affinity of compounds measured at the β1AR and β2AR: Affinity values
for β-adrenoceptor ligands measured in CHO cells expressing the β1AR or the
β2AR using 10 nM of BODIPY-TMR-CGP in the HTS format fluorescent ligand
binding assay.
β1AR β2AR
pKi n pKi n
Propranolol 8.89 ± 0.16 3 9.00 ± 0.09 3
CGP 20712A 9.68 ± 0.12 3 5.68 ± 0.06 3
ICI 118,551 7.40 ± 0.03 3 8.73 ± 0.07 3
Values represent mean ± SEM from three experiments performed in triplicate.
lower than CGS15943 (Figure 4, Table 4). Five further hits
(BIO, rottlerin, quercetin, PD173952 and kenpaullone) only
displaced the binding of CA200645 at the highest concentration
tested (10µM), prohibiting an accurate affinity determination.
For those four compounds showing micromolar affinity, the
selectivity of their interaction with the A3AR was determined
by investigating their ability to bind to A1AR and β2AR. Both
K114 and retinoic acid p-hydroxyanilide inhibited the binding
of CA200645 at the A1AR with similar affinity to that observed
at the A3AR. SU 6656 only inhibited binding at the highest
concentration tested and the affinity was not calculated. None
of the other compounds showed any measureable activity at
the A1AR. When tested in CHO cells expressing the β2AR,
no significant inhibition of BODIPY-TMR-CGP binding was
observed for any of the 10 compounds screened but the control
β2AR antagonist propranolol had the expected affinity (pKi =
8.72 ± 0.14, n = 3). There was an increase in fluorescence in
the presence of 10µM SU 6656 (128.4 ± 18.4%). However this
was small compared to the increase seen with 10 nM BODIPY-
TMR-CGP and the large increase in fluorescence in the presence
of BIO (pEC50 = 5.84 ± 0.13). This is likely to be due to these
compounds interfering with the BODIPY-TMR fluorescence
signal, which was not observed when using the more red-shifted
BODIPY 630/650 fluorophore in the A1AR and A3AR binding
assays.
Molecular Modeling of Selected LOPAC
Hits at the A3AR
Using our previously established homology model of the human
A3AR (Vernall et al., 2013) we sought to investigate potential
binding poses for the three sub-micromolar compounds
(retinoic acid p-hydroxyanilide (fenretinide), K114 and
SU 6656) identified in the LOPAC screen which did not
have previous literature precedent for interacting with
this receptor sub-type. Using the commercially available
docking software, CLC Drug Discovery Workbench, ligand
and receptor binding pocket preparation was followed by
targeted ligand docking. The highest scoring docked poses
for K114, SU 6656 and retinoic acid p-hydroxyanilide
were selected and are illustrated in Figure 5. All three
compounds were able to engage via plausible poses to the
A3R within the vicinity of the orthosteric binding pocket of this
receptor.
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FIGURE 3 | Screening the LOPAC library against the A3AR. Example of the data generated from one plate of compounds from the LOPAC library. Each plate
contained 40 compounds (each at 10µM final concentration) from the LOPAC library in duplicate along with four basal and four MRS1220 (10µM) controls, also in
duplicate. The fluorescence intensities obtained on the PHERAstar FS from this plate are shown as mean and range of duplicates with the hits highlighted in red and
adenosine indicated in blue. The plate shown is a representative plate of one of the three experiments performed using these compounds and the inhibition data for all
compounds screened can be found in Supporting Information Table 1.
DISCUSSION
Fluorescent ligands for GPCRs are a valuable tool in the study
of multiple aspects of receptor pharmacology and they are a
potential replacement for radiolabelled ligands in saturation and
equilibrium binding studies to determine the affinity of labeled
and unlabeled ligands (Stoddart et al., 2016). In this study, we
aimed to further develop a previously described fluorescence
based live cell binding assay that used a HCS system (Stoddart
et al., 2012) to an assay that could be performed with un-tagged
receptors on a HTS system. To this end, we chose the PHERAstar
FS fluorescent plate reader since it allowed the determination of
the optimal focal height for the fluorescence read and multiple
scans per well. Use of the HTS system to obtain data resulted in a
marked reduction in the time each 96-well plate took to process;
from around 40 minutes per plate on the confocal HCS system
for data collection and analysis to less than 3 minutes for the
HTS system. This also produced a significant reduction in the
amount of data that needed to be stored; 500 Mb per plate for
HCS versus 160 Kb for HTS. Using the A3AR as a model system,
we demonstrated that the data generated on the HTS system
was in close agreement to that obtained on the HCS system,
validating this system as a higher throughput methodology
that would be essential for screening large compound
libraries using fluorescence-based binding assays in whole
cells.
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TABLE 3 | Known A3AR ligands in the LOPAC library: Compounds within the LOPAC library that have known activity at adenosine receptors, their rank order in the full
screen and the % of 25 nM CA200645 binding in the presence of 10µM of these compounds.
Name Agonist or antagonist LOPAC description % Total CA200645
binding
Rank
CGS 15943 Antagonist Potent non-selective adenosine receptor antagonist 30.0 ± 3.0 9
2-Cl-IB-MECA Agonist A3 adenosine receptor agonist 32.3 ± 6.1 12
IB-MECA Agonist Selective A3 adenosine receptor agonist 36.3 ± 4.0 18
NECA Agonist Adenosine receptor agonist 38.1 ± 4.3 20
HEMADO Agonist A3 adenosine receptor agonist 40.1 ± 10.5 24
APNEA Agonist Non-selective adenosine receptor agonist 41.0 ± 7.2 26
1,3-dipropyl-8-p-sulfophenylxanthine Antagonist Adenosine receptor antagonist (slight selectivity for A1 over A2) 42.3 ± 4.8 29
AB-MECA Agonist High affinity A3 adenosine receptor agonist 49.5 ± 5.8 38
2-CADO Agonist Adenosine receptor agonist with selectivity for A1 over A2 51.0 ± 6.7 43
SCH 58261 Antagonist A2A adenosine receptor antagonist 52.2 ± 5.4 47
CV1808 Agonist Selective A2 adenosine receptor agonist 53.3 ± 19.9 56
DPCPX Antagonist Selective A1 adenosine receptor antagonist 56.3 ± 3.4 58
FSCPX Antagonist Irreversible A1 adenosine receptor antagonist 57.5 ± 23.0 63
MRS 1523 Antagonist Selective A3 adenosine receptor antagonist in rat 58.3 ± 11.4 64
Various methods using fluorescent ligands to measure ligand
binding at GPCRs have been recently developed, each using a
different approaches to measure the fluorescence of the bound
ligand, including flow cytometry (Young et al., 2005; Hara et al.,
2009; Kozma et al., 2013), fluorescence polarization (Cornelius
et al., 2009; Kecskes et al., 2010) and resonance energy transfer
based systems (Zwier et al., 2010; Stoddart et al., 2015a).
Each method has advantages and disadvantages, for instance
ligand depletion (fluorescence polarization) and the need to
tag the receptor of interest (BRET and FRET). One limitation
of the simple fluorescent intensity measurement used in the
system described here is the potential for a low signal/noise
ratio as a result of high levels of non-specific binding and
the use of whole cells. As this technique measures total well
fluorescence intensity it will be affected by both high levels of
non-specific membrane binding and also non-specific uptake
of the fluorescent ligand into the cells. As an example of this,
for the A3AR the maximal reduction in the levels of CA200645
fluorescence measured in the presence of unlabeled ligands was
60% whilst that with BODIPY-TMR-CGP for the β1AR was
only 20% (Figures 1C, 2B). This small signal/noise ratio for this
ligand at the β1AR has been observed previously (Gherbi et al.,
2014), although it is notable that even under these conditions,
the method described here still allowed us to generate robust
data within this small signal/noise window. The proximity-
based assays (e.g., NanoBRET; Stoddart et al., 2015a) overcome
this issue but they obviously require genetic modification of
the extracellular N-terminus of the receptor with a fluorescent
or luminescent protein, which precludes their use on native
receptors—amain aim of the assay developed in this study. What
is also clear from this point of view, is that the limit of this
signal to noise ratio is likely to be highly dependent on both the
pharmacological and photophysical properties of the fluorescent
ligand, as we have previously demonstrated (Vernall et al., 2013).
To progress the use of this assay to use with endogenously
expressed untagged receptors, consideration should also be given
to fluorescent ligand selectivity in situations where multiple
receptor subtypes are often co-expressed; this is particularly true
for adenosine receptors. To this end, the demonstration that this
assay also works with a highly A3AR selective ligand, AV039
(Vernall et al., 2012) is important.
To demonstrate the utility of this assay system for compound
screening, we investigated if we could identify known ligands
for the A3AR within a library of pharmacologically active
compounds (LOPAC). Within the LOPAC library there were 37
compounds identified as ligands for adenosine receptors. For the
1,263 compounds screened, we defined a hit as a compound that
inhibited more than 40% of the total CA200645 binding. Using
these criteria, we identified 67 hits, of which 14 had previously
described activity at adenosine receptors (Table 3). Of these, four
were the known A3R selective agonists, 2-Cl-IB-MECA (Gallo-
Rodriguez et al., 1994), IB-MECA (Klotz et al., 1998), AB-MECA
(Klotz et al., 1998) and HEMADO (Klotz et al., 2007), and the
A3R selective antagonist MRS1523 (Li et al., 1998). A further five
compounds were known to be non-selective at this adenosine
receptor subtype [CGS15943 (Ongini et al., 1999), NECA (Gao
et al., 2004), APNEA (Gao et al., 2004), 2-CADO (van Galen
et al., 1994) and 1,3-dipropyl-8-p-sulfophenylxanthine (Daly
et al., 1985)]. The remaining four compounds were SCH 58261,
CV1808, DPCPX and FSCPX. SCH 58261 is widely described as
an A2A selective and DPCPX as an A1AR-selective antagonist,
and both retain affinity in theµM range for the A3AR (Ongini
et al., 1999; Stoddart et al., 2012). FSCPX is an irreversible
antagonist at the A1AR (vanMuijlwijk-Koezen et al., 2001) but to
date it had not been tested at other adenosine receptor subtypes.
Our data from this screen indicates that FSCPX is likely to
retain activity at the A3R at least in the lowµM range and this
is also true for CV1808 that has been described as an agonist
at the A2AAR (Dionisotti et al., 1997). A variety of different
compounds that act at different (i.e., non-A3AR) adenosine
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FIGURE 4 | Competition binding curves at the A1AR, A3AR, and β2AR for
three hits identified from the LOPAC library. CHO cell lines stably expressing
A1AR (A), A3AR (B), or β2AR (C) were incubated with 25 nM CA200645
(A3AR and A1AR) or 10 nM BODIPY-TMR-CGP (β2AR) in the absence or in the
presence of increasing concentrations of the indicated compounds. Values are
mean ± SEM from three independent experiments performed in triplicate.
receptors were included in the library and as expected were not
identified as hits in our screen (Supporting Information Table 1).
These included A1AR selective agonists and antagonists such as
R-PIA (Klotz et al., 1998) and CPT (Dalpiaz et al., 1998), A2AAR
selective agonists and antagonists such as CGS 21680 (Klotz
et al., 1998) and CSC (Jacobson et al., 1993), and the A2BAR
selective antagonist alloxazine (Ji et al., 2001). A variety of low
affinity non-selective antagonists and agonists were also present
in the library including adenosine, theophylline, caffeine and
paraxanthine that have reported affinity at the A3AR in the 13-
100µM range (Jacobson et al., 1999; Fredholm et al., 2001). Due
to the concentration of CA200645 (25 nM) used in the primary
screen only compounds with an affinity of <10µM would be
expected to be identified as a hit. Overall, the assay performed
well at identifying all the compounds with known activity at the
A3AR.
We found three compounds in the library that displayed
unexpected sub-micromolar affinity at the A3AR (Figure 4,
Table 4). These were K114, retinoic acid p-hydroxyanilide and
SU 6556. K114 is used to identify amyloid lesions from
Aβ peptide, α-synuclien and tau through an increase in its
fluorescence upon binding to these lesions. It is has minimal
fluorescence in aqueous solution and has emissionmaxima of 550
nm that is unlikely to interfere with the emission of BY630 at 650
nm (Crystal et al., 2003). In addition, the assay described here
monitors a decrease in fluorescence in the presence of inhibitors
that would mean it would be more likely to give false-negatives
rather than false-positives. Retinoic acid p-hydroxyanilide, also
known as fenretinide or 4-HPR, is an analog of retinoic acid
and is a potential therapy in the treatment of cancer due to its
ability to induce apoptosis (Wu et al., 2001). It is possible that
it was causing apoptosis of the cells in our assay system leading
to a concurrent decrease in fluorescence but as the presence of
retinoic acid p-hydroxyanilide had no effect in cells expressing
the β2AR this is unlikely to be the case (Figure 4). SU6556 is a
Src kinase inhibitor that has also been found to inhibit a variety of
other kinases including Aurora C and AMPK (Bain et al., 2007).
It also displayed slight selectivity for the A3AR over A1AR.
Docking of the sub-micromolar compounds identified in the
LOPAC screen provided a plausible set of binding poses within
the vicinity of the established orthosteric A3AR binding pocket
(Figure 5). K114 bound in a fully extended form with one of the
terminal phenols optimally positioned to engage in a hydrogen
bond interaction with the side-chain of Thr94. Meanwhile,
the remaining vinyl-linked aromatic moieties pass through a
hydrophobic channel created by Ile76, Val169, Leu90, Leu246,
Ile249, Leu264, Ile268, and Phe168; the latter engaging via a face-
to-face pi-stacking interaction. SU 6656 favored binding higher
up in the orthosteric pocket with the 4,5,6,7-tetrahydroindolyl
portion of the molecule engaging in a face-to-face interaction
with Phe168, with the hydrophobic interactions predominating
with Leu90, Val65, Ile268, and Leu246. Finally, retinoic acid p-
hydroxyanilide displayed a binding pose passing through the
same hydrophobic channel observed with K114. The 1,3,3-
trimethylcyclohex-1-enyl region of the molecule was positioned
deepest into the binding pocket engaging in hydrophobic
interactions with residues Leu246, Ile249, Met177, and Phe168.
The p-hydroxyanilde region of the molecule was positioned in
such a way as to allow a face-to-edge interaction with Tyr265
at the top of transmembrane helix 7. With the predominance
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TABLE 4 | Affinity of selected hits from the LOPAC library at the A3AR, A1AR, and β2AR: Compounds were tested on CHO cells expressing the A3AR, A1AR, and β2AR
in the HTS format fluorescent ligand binding assay using 25 nM CA200645 as the tracer for A3AR and A1AR and 10 nM of BODIPY-TMR-CGP for β2AR.
Position in primary screen Compound A3AR A1AR β2AR
pKi pKi % Total binding at 10µM
2 SU 6656 6.17 ± 0.08 ND 128.4 ± 18.4
5 K114 6.43 ± 0.04 6.56 ± 0.11 95.8 ± 5.5
8 Retinoic acid p-hydroxyanilide 6.13 ± 0.18 6.04 ± 0.21 102.7 ± 5.1
9 CGS 15943 7.24 ± 0.14 8.14 ± 0.09 115.4 ± 5.0
Data represents mean ± SEM from three experiments performed in triplicate. ND, Not determined as accurate curve could not be generated.
FIGURE 5 | Molecular modeling simulation of K114, SU 6656 and retinoic acid p-hydroxyanilide binding to the A3AR. A side-on (A,C,E) and top-down (B,D,F) view
of the top scoring binding poses for K114, SU 6656 and retinoic acid p-hydroxyanilide (dark gray liquorice coloring) respectively, bound into our previously reported
A3AR receptor homology model (Vernall et al., 2013). Previously identified amino acid side chain residues associated with the orthosteric binding pocket (Squarcialupi
et al., 2013) are represented in light gray liquorice coloring and labeled alongside the TM loop regions for clarity.
of aromatic and hydrophobic interactions observed between the
receptor and the three ligands discussed, this would seem to
correlate well with the experimental binding affinities whilst also
offering the potential to undertake productive modifications of
these compounds to potentially enhance their overall binding
interactions.
In conclusion, we have shown that a simple intensity based
fluorescent ligand binding assay can be modified to work
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in a potentially high throughput format, giving significant
advances in both speed and data volume compared to previous
high content versions. The assay allows screening of a small
compound library in live cells, and can assess binding to the
unmodified native receptors. The assays performed well under
test conditions, identifying both known adenosine receptor
ligands in a focused library as well as novel potential ligand
scaffolds. Further work on establishing this assay to screen at
endogenous A3AR in a mixed receptor background will be
important to allow subsequent screens to be performed under
more physiological conditions.
EXPERIMENTAL PROCEDURES
Chemicals
Known GPCR antagonists were purchased from Tocris
Bioscience and G418 was obtained from Invitrogen. Fetal calf
serum was obtained from PAA Laboratories and L-glutamine
from Lonza. All other biological reagents were obtained
from Sigma-Aldrich. CA200645 was obtained from CellAura
Technologies. BODIPY-TMR-CGP (BODIPY-TMR-(±)-CGP
12177) was purchased from Molecular Probes. AV039 and
AV019 were synthesized in house as previously described
(Vernall et al., 2012). The LOPAC library was obtained from
Sigma-Aldrich.
Cell Culture
CHO-K1 cells stably expressing the human A3AR (Vernall
et al., 2012), β1AR (Guo et al., 2012), β2AR (Baker et al.,
2002) or the human A1AR (May et al., 2010) were maintained
in DMEM/F12 medium containing 10% fetal calf serum and
2 mM L-glutamine at 37◦C in a humidified atmosphere of
air/CO2 (19:1).
Fluorescence Competition Binding Assay
CHO cells stably expressing the A3AR, A1AR, β1AR or β2AR
were seeded into the central 60 wells (for high content confocal
analysis) or every well (high throughput analysis) of a 96-well
clear-bottomed, black-walled plate (Greiner BioOne) and grown
to confluency. On the day of experiment, normal growthmedium
was removed and cells washed twice with HEPES-buffered saline
solution (HBSS; 10 mM HEPES, 10 mM glucose, 145 mM
NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM sodium pyruvate, 1.3
mM CaCl2, 1.5 mM NaHCO3, pH 7.4) pre-warmed to 37◦C.
Fresh HBSS was added to each well followed by the addition
of the required concentration of unlabeled compound and the
respective fluorescent ligands (25 nM CA200645, 5 nM AV039
or 10 nM BODIPY-TMR-CGP). Cells were incubated for 1h
at 37◦C/5% CO2. Buffer was then removed from each well,
cells washed once in HBSS and fresh HBSS added at room
temperature. Plates were then immediately subjected to high
content or HTS analysis as detailed below.
High Content Screening
High content analysis was conducted as previously described
(Stoddart et al., 2012). Briefly, plates were imaged using an
ImageXpress Ultra confocal plate reader, which captured four
central images per well using a Plan Fluor 40x NA0.6 extra-
long working distance objective. CA200645 was excited at 635
nm and emission collected through a 640–685 nm band pass
filter. Total image intensity was obtained using a modified
multi-wavelength cell scoring algorithm within the MetaXpress
software (MetaXpress 2.0, Molecular Devices).
High Throughput Screening
High throughput analysis was performed using a PHERAstar FS
plate reader (BMG Technologies). Fluorescent intensity of each
well was assessed by bottom scanning using the following optical
modules: excitation 540 nm and emission 590 nm (for BODIPY-
TMR-CGP-labeled cells), or excitation 630 nm and emission 650
nm (for the BY630 compounds CA200645 and AV039). Optimal
focal height was determined automatically and total fluorescence
intensity was assessed by taking 81 reads per well.
Screening of the LOPAC Library of
Pharmacological Active Compounds
The LOPAC compound library contained 1263 compounds and
each compound was provided as a pre-dissolved solution in 10
mM in DMSO. Compound plates containing 2µl of compound
per well were provided by theUniversity of NottinghamManaged
Compound Collection. Each plate contained 40 compounds from
the LOPAC library together with positive and blank control
samples. For the blank controls, 2µl of DMSO was added per
well and for the positive controls the A3AR antagonist MRS1220
(10µM final concentration) was used. The compounds were
diluted to 100µM in HBSS prior to assay. Each compound
was tested in duplicate at a final concentration of 10µM on
three separate experimental days. Experiment was carried out as
detailed above using the A3AR expressing cell line and 25 nM
CA200645 as the tracer ligand. Data were normalized on a per
plate basis to the fluorescence observed in blank control wells.
The 67 compounds that inhibited by more than 40% the
total binding of CA200645 compared to blank controls were
classed as hits. From this list 16 compounds were selected for
secondary screening to determine their IC50 values and binding
affinity. This was achieved by investigating the effect of increasing
concentrations of each inhibitor on the specific binding of 25 nM
CA200645 or 10 nM BODIPY-TMR-CGP in cells expressing the
A3AR, A1AR or β2AR.
Molecular Modeling
Using our previously reported homology model of the
human A3AR (Vernall et al., 2013) and the CLC Drug
Discovery Workbench software package (Version 3.0.2,
Qiagen, Netherlands), the protein target was prepared with
no water molecules present. Before setting up the docking
experiments, the binding site was generated as a 13 Å sphere
centered around the established orthosteric pocket. All small
molecules were constructed using ChemDraw Professional
16.0 (CambridgeSoft, Cambridge, MA, USA) and imported
into the docking programme using the Balloon PlugIn
(http://users.abo.fi/mivainio/balloon) (Vainio and Johnson,
2007) to afford the lowest energy conformer for each ligand.
During the docking process, each ligand underwent 1000
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individual iterations, with the conformation of each ligand
set as flexible, allowing full movement around all rotatable
bonds, whilst the protein was held as a rigid structure. The best
scoring pose for each ligand was returned using the PLANTSPLP
algorithm to determine that docking score (Korb et al., 2009)
and the best ranked compounds were selected and their binding
residues observed using the CLC Drug Discovery Workbench
visualization tool.
Data Analysis
Competition binding curves were fitted to the following equation
using GraphPad Prism 5 (GraphPad Software):
% inhibition of specific binding =
100× [A]
[A]+ IC50
where [A] is the concentration of competing drug and IC50 is
the molar concentration of ligand required to inhibit 50% of the
specific binding of a fixed concentration [L] of the appropriate
fluorescent ligand. The IC50 values obtained were converted to
Ki values using the following equation:
Ki =
IC50
1+ [L]KD
where [L] is the concentration and KD is the equilibrium
dissociation constant of the fluorescent ligand. The KD values
for the fluorescent ligands used were 11.0 nM and 3.11 nM for
CA200645 at the A1AR and A3AR respectively (Stoddart et al.,
2012). KD values for BODIPY-TMR-CGP were taken from Baker
et al. (2003).
The Z′ values were calculated on a per plate basis using the
following equation:
Z′ = 1−
3(σp + σn)
µp − µn
where µp and σp are the mean and standard deviation from the
control wells (DMSO only) and µn and σn are the mean and
standard deviation from the MRS1220 treated wells.
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